Jonathan Mow
Chief Executive Officer chez PHASEBIO PHARMACEUTICALS, INC.
Profil
Jonathan P.
Mow was the founder of Corus Pharma, Inc. (founded in 2001) where he held the title of Secretary & VP-Commercial & Business Development from 2001 to 2006.
He is currently the Chief Executive Officer & Director at PhaseBio Pharmaceuticals, Inc. (since 2012) and the Chief Executive Officer at Veralox Therapeutics, Inc. (since 2023).
Mr. Mow's former positions include Director-Worldwide Oncology Marketing at Bristol Myers Squibb Co. (1995-1997), Vice President-Business Development at Amylin Pharmaceuticals, Inc. (2007-2012), and Principal roles at PathoGenesis Corp, Syntex Laboratories, Inc., and Lederle International.
Mr. Mow's education includes an undergraduate degree from the University of California, Berkeley and an MBA from the Tepper School of Business.
Postes actifs de Jonathan Mow
| Sociétés | Poste | Début |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Chief Executive Officer | 01/09/2014 |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Chief Executive Officer | 20/06/2023 |
Anciens postes connus de Jonathan Mow
| Sociétés | Poste | Fin |
|---|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Corus Pharma, Inc.
 Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Founder | 01/01/2006 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/1997 |
| Syntex Laboratories, Inc. | Corporate Officer/Principal | - |
| Lederle International | Corporate Officer/Principal | - |
Formation de Jonathan Mow
| University of California, Berkeley | Undergraduate Degree |
| Tepper School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
PathoGenesis Corp
 PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a private company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Health Technology |
Corus Pharma, Inc.
Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Health Technology |
| Syntex Laboratories, Inc. | |
| Lederle International | |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Health Technology |
